Promising Response Data for Menin Inhibitor in Relapsed/Refractory AML

abdulmanannet77@gmail.comSeptember 5, 2025

0 2 Less than a minute

https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c

$Promising Response Data for Menin Inhibitor in Relapsed/Refractory AML$ (MedPage Today) — HOUSTON — Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor.
A pooled analysis of data from…